Navigation Links
Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
Date:3/2/2009

SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that Patrick Mahaffy has been appointed to the Company's Board of Directors to fill an existing vacancy on the board.

Mr. Mahaffy brings significant biotechnology and pharmaceutical executive management experience. He was the founder of Pharmion Corporation and served as its President and CEO from its inception through its acquisition eight years later. Under Mr. Mahaffy's leadership, Pharmion successfully acquired, developed and gained approval for several oncology products in the U.S. and Europe and achieved significant revenues and sustained growth from those products until its acquisition by Celgene Corporation for $2.9 billion in March 2008. Mr. Mahaffy is presently creating a new company dedicated to acquiring and developing oncology drug products.

"Patrick has a proven track record in successfully managing all facets of drug development and commercialization, and his experience will be incredibly valuable as we complete the Phase 3 program for Contrave, our lead obesity product candidate," said Eckard Weber, M.D., Executive Chairman and Interim President and CEO. "In addition, his knowledge and experience in strategic business development will be important as we continue to explore partnership opportunities and execute on broader business strategies."

Prior to co-founding Pharmion, Mr. Mahaffy was President and CEO of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals Inc. from 1992 until 1999. He is credited for developing corporate partnerships with Eli Lilly and Co., Systemix/Sandoz, Schering AG and Becton, Dickinson and Co. He took NeXstar Pharmaceuticals public in 1994 and in 1995 acquired publicly-traded company Vestar. In July 1999, Gilead acquired NeXstar Pharmaceuticals for $800 million. Mr. Mahaffy received a B.A. from Lewis and Clark College and an M.A. from Columbia School of International Affairs.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology: